Risky Business: Government’s Biomarker Efforts Can Go Where Pharma Won’t
Government research on biomarkers should venture into areas of risky development where pharmaceutical companies will not, a National Cancer Institute official told the Institute of Medicine's National Cancer Policy Forum March 20
You may also be interested in...
FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials